meloxicam - Substance Summary (SID 10369)
structure in first source
  Table of Contents
 Drug and Chemical Information: (Total:1)
Medication Information
Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each pale yellow to yellow tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically  Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet contains 7.5mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each yellow tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal antiinflammatory drugs (NSAIDs). Each tablet contains meloxicam 7.5 mg or 15 mg for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of non-steroidal anti-inflammatory drugs (NSAIDs). Each tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Eachtablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of non-steroidal anti-inflammatory drugs (NSAIDs). Each tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each pastel yellow MOBIC tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Each bottle of MOBIC oral Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet contains 7.5mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Meloxicam, an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). Each tablet contains 7.5 mg or 15 mg meloxicam for oral administration. Meloxicam is chemically designated as Anti-Inflammatory Agents, Non-Steroidal
- Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain NSAIDs also may inhibit lipoxygenase enzymes or TYPE C PHOSPHOLIPASES or may modulate T-cell function. (AMA Drug Evaluations Annual, 1994, p 1814-5)  | Cyclooxygenase Inhibitors
- Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme ... Cyclooxygenase Inhibitors
- Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. |
Pharmacological Classification Literature Literature Keyword Mining Tool
 Data Source: 
Depositor: KEGGExternal ID: C08169
 Properties Computed from Structure:
| Molecular Weight | 351.40072 [g/mol] | | Molecular Formula | C14H13N3O4S2 | | XLogP3 | 3.4 | | H-Bond Donor | 2 | | H-Bond Acceptor | 7 | | Rotatable Bond Count | 2 | | Tautomer Count | 8 | | Exact Mass | 351.034747 | | MonoIsotopic Mass | 351.034747 | | Topological Polar Surface Area | 99.6 | | Heavy Atom Count | 23 | | Formal Charge | 0 | | Complexity | 628 | | Isotope Atom Count | 0 | | Defined Atom StereoCenter Count | 0 | | Undefined Atom StereoCenter Count | 0 | | Defined Bond StereoCenter Count | 1 | | Undefined Bond StereoCenter Count | 0 | | Covalently-Bonded Unit Count | 1 |
Descriptors Computed from Structure:
IUPAC Name: (3E)-3-[hydroxy-[(5-methyl-1, 3-thiazol-2-yl)amino]methylidene]-2-methyl-1, 1-dioxobenzo[e]thiazin-4-one
Canonical SMILES: CC1=CN=C(S1)NC(=C2C(=O)C3=CC=CC=C3S(=O)(=O)N2C)O
Isomeric SMILES: CC1=CN=C(S1)N/C(=C\2/C(=O)C3=CC=CC=C3S(=O)(=O)N2C)/O
InChI: InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10
(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+
InChIKey: DWMREKMVXIFPFM-ACCUITESSA-N
Substance Information:
Depositor-Supplied Comments:
CAS: 71125-38-7
Same as: D00969
|
|
|
|
  |
| Compound ID | 5281106 |
| | Molecular Weight | 351.40072 [g/mol] |
| | Molecular Formula | C14H13N3O4S2 |
| | XLogP3 | 3.4 |
| | H-Bond Donor | 2 |
| | H-Bond Acceptor | 7 |
|
 Links |
|
